NKARTA INC

RA Capital’s 37,000‑contract option buy at NKARTA fuels insider confidence and hints at future funding, while noting dilution risks and the company’s strong social‑media buzz.

Insider buying at Nkarta signals confidence in its biotech pipeline—President Mahmood Nadir and execs are staking options on a $2.74 peak, hinting at future upside.